NOVN.CH

92.14

-1.05%↓

SOON.CH

234.2

+1.96%↑

NOVN.CH

92.14

-1.05%↓

SOON.CH

234.2

+1.96%↑

NOVN.CH

92.14

-1.05%↓

SOON.CH

234.2

+1.96%↑

NOVN.CH

92.14

-1.05%↓

SOON.CH

234.2

+1.96%↑

NOVN.CH

92.14

-1.05%↓

SOON.CH

234.2

+1.96%↑

Search

Bachem Holding AG

Closed

SectorHealthcare

57.2 -1.04

Overview

Share price change

24h

Current

Min

57.2

Max

58

Key metrics

By Trading Economics

Income

84M

Sales

365M

P/E

Sector Avg

35.656

39.857

EPS

1.13

Dividend yield

1.47

Profit margin

23.042

Employees

2,207

EBITDA

118M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+30.06% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.47%

2.42%

Next Earnings

24 lip 2025

Market Stats

By TradingEconomics

Market Cap

4.3B

Previous open

58.24

Previous close

57.2

News Sentiment

By Acuity

10%

90%

8 / 376 Ranking in Healthcare

Bachem Holding AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 gru 2024, 11:00 UTC

Market Talk

Bachem Has Challenging Years Ahead With Strong Capital Expenditure -- Market Talk

Peer Comparison

Price change

Bachem Holding AG Forecast

Price Target

By TipRanks

30.06% upside

12 Months Forecast

Average 75.5 CHF  30.06%

High 78 CHF

Low 73 CHF

Based on 2 Wall Street analysts offering 12 month price targets forBachem Holding AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Sentiment

By Acuity

8 / 376 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.